1-2 of 2
Rossella Bruno
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Crizotinib in ROS1 and MET Deregulated NSCLC—Response

Lorenza Landi, Rossella Bruno, Gabriella Fontanini, Federico Cappuzzo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (7): 1775.
https://doi.org/10.1158/1078-0432.CCR-20-0026
Published: 01 April 2020
View article titled, Crizotinib in <em>ROS1</em> and <em>MET</em> Deregulated NSCLC—Response
Open the PDF for Crizotinib in <em>ROS1</em> and <em>MET</em> Deregulated NSCLC—Response in another window
Journal Articles

Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial

Lorenza Landi, Rita Chiari, Marcello Tiseo, Federica D'Incà, Claudio Dazzi, Antonio Chella, Angelo Delmonte, Laura Bonanno, Diana Giannarelli, Diego Luigi Cortinovis, Filippo de Marinis, Gloria Borra, Alessandro Morabito, Cesare Gridelli, Domenico Galetta, Fausto Barbieri, Francesco Grossi, Enrica Capelletto, Gabriele Minuti, Francesca Mazzoni, Claudio Verusio, Emilio Bria, Greta Alì, Rossella Bruno, Agnese Proietti, Gabriella Fontanini, Lucio Crinò, Federico Cappuzzo
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (24): 7312–7319.
https://doi.org/10.1158/1078-0432.CCR-19-0994
Published: 13 December 2019
View article titled, Crizotinib in <em>MET</em>-Deregulated or <em>ROS1</em>-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
Open the PDF for Crizotinib in <em>MET</em>-Deregulated or <em>ROS1</em>-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial in another window
Includes: Supplementary data